Although the KRAS protein abundance is indeed lower in tumors compared with normal controls, it is obvious that tumors with mutant KRAS have higher KRAS abundance compared with those without mutant KRAS (Fig. 2c), suggesting the dependence of CRC tumors on the mutant but not wild-type KRAS protein. This evidence concerns the gene KRAS and colorectal carcinoma.